{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:44:56Z","timestamp":1759160696673,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Janssen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12985-017-0760-2","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T08:42:17Z","timestamp":1496220137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055\/ritonavir, with and without ribavirin, and JNJ-56914845"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4356-2199","authenticated-orcid":false,"given":"Leen","family":"Vijgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Thys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vandebosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Van Remoortere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Verloes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"De Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"760_CR1","unstructured":"World Health Organization. WHO Fact Sheet 164 - Hepatitis C 2012. \nhttp:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/\n\n. Accessed 23 Nov 2016."},{"key":"760_CR2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756283X15587481","volume":"8","author":"BP Lam","year":"2015","unstructured":"Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015;8:298\u2013312.","journal-title":"Therap Adv Gastroenterol"},{"key":"760_CR3","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87\u201399.","journal-title":"J Hepatol"},{"key":"760_CR4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2015.09.009","volume":"64","author":"C Hezode","year":"2016","unstructured":"Hezode C, Bronowicki JP. Ideal oral combinations to eradicate HCV: The role of ribavirin. J Hepatol. 2016;64:215\u201325.","journal-title":"J Hepatol"},{"key":"760_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12876-017-0580-2","volume":"17","author":"S Bourgeois","year":"2017","unstructured":"Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arasteh K, et al. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055\/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. BMC Gastroenterol. 2017;17:26.","journal-title":"BMC Gastroenterol"},{"key":"760_CR6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","volume":"62","author":"O Lenz","year":"2015","unstructured":"Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies. J Hepatol. 2015;62:1008\u201314.","journal-title":"J Hepatol"},{"key":"760_CR7","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756\u201365.","journal-title":"Lancet"},{"key":"760_CR8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2014.12.031","volume":"62","author":"C Moreno","year":"2015","unstructured":"Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, et al. Efficacy and safety of simeprevir with PegIFN\/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol. 2015;62:1047\u201355.","journal-title":"J Hepatol"},{"key":"760_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.28422","volume":"64","author":"E Lawitz","year":"2016","unstructured":"Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360\u20139.","journal-title":"Hepatology"},{"key":"760_CR10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hep.28467","volume":"64","author":"P Kwo","year":"2016","unstructured":"Kwo P, Gitlin N, Nahass R, Bernstein B, Rojter S, Schiff E, et al. Simeprevir plus sofosbuvir (12 and 8\u00a0weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64:370\u201380.","journal-title":"Hepatology"},{"key":"760_CR11","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1128\/AAC.00245-12","volume":"56","author":"B Devogelaere","year":"2012","unstructured":"Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, et al. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother. 2012;56:4676\u201384.","journal-title":"Antimicrob Agents Chemother"},{"key":"760_CR12","volume-title":"Human safety, pharmacokinetics and antiviral activity of TMC647055, a novel HCV non-nucleoside polymerase inhibitor","author":"J Leempoels","year":"2011","unstructured":"Leempoels J, Reesink H, Bourgeois S, Vijgen L, Rouan MC, Vandebosch A, et al. Human safety, pharmacokinetics and antiviral activity of TMC647055, a novel HCV non-nucleoside polymerase inhibitor. 2011. \nhttp:\/\/www.natap.org\/2011\/AASLD\/AASLD_04.htm\n\n. Accessed 23 Nov 2016."},{"key":"760_CR13","doi-asserted-by":"crossref","first-page":"S483","DOI":"10.1016\/S0168-8278(13)61189-7","volume":"58","author":"S Bourgeois","year":"2013","unstructured":"Bourgeois S, Reesink HW, Leempoels J, Vijgen L, Rouan MC, Marien K, et al. Combination therapy of TMC647055 with simeprevir (TMC435) in chronic hepatitis C patients [abstract]. J Hepatol. 2013;58:S483.","journal-title":"J Hepatol"},{"key":"760_CR14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.01363-13","volume":"58","author":"J Walker","year":"2014","unstructured":"Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, et al. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother. 2014;58:38\u201347.","journal-title":"Antimicrob Agents Chemother"},{"key":"760_CR15","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1128\/AAC.00910-13","volume":"57","author":"DA Wilfret","year":"2013","unstructured":"Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, et al. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob Agents Chemother. 2013;57:5037\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"760_CR16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-62703-484-5_12","volume":"1030","author":"D Koletzki","year":"2013","unstructured":"Koletzki D, Pattery T, Fevery B, Vanhooren L, Stuyver LJ. Amplification and sequencing of the hepatitis C virus NS3\/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b. Methods Mol Biol. 2013;1030:137\u201349.","journal-title":"Methods Mol Biol"},{"key":"760_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jviromet.2015.04.022","volume":"221","author":"K Thys","year":"2015","unstructured":"Thys K, Verhasselt P, Reumers J, Verbist BM, Maes B, Aerssens J. Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants. J Virol Methods. 2015;221:29\u201338.","journal-title":"J Virol Methods"},{"key":"760_CR18","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/JVI.01980-09","volume":"84","author":"O Nyanguile","year":"2010","unstructured":"Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, et al. 1a\/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus. J Virol. 2010;84:2923\u201334.","journal-title":"J Virol"},{"key":"760_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-62703-484-5_9","volume":"1030","author":"L Vijgen","year":"2013","unstructured":"Vijgen L, Verbeeck J, van Kerckhove B, Berke JM, Koletzki D, Fanning G, et al. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3\/4A protease inhibitors. Methods Mol Biol. 2013;1030:105\u201317.","journal-title":"Methods Mol Biol"},{"key":"760_CR20","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1128\/AAC.01444-15","volume":"59","author":"T Verbinnen","year":"2015","unstructured":"Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O. In vitro activity of simeprevir against hepatitis C virus genotype-1 clinical isolates and its correlation with NS3 sequence and site-directed mutants. Antimicrob Agents Chemother. 2015;59:7548\u201357.","journal-title":"Antimicrob Agents Chemother"},{"key":"760_CR21","unstructured":"Huang W, Newton A, Cook J, Toma J, Frantzell A, Choe S, et al. Development of recombinant replicon report assays for characterization of HCV NS5A and NS3\/4A protease inhibitors. Antiviral Ther. 2011;16(Suppl. 1):A29."},{"key":"760_CR22","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O, Verbinnen T, Lin T-I, Vijgen L, Cummings MD, Lindberg J, et al. In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54:1878\u201387.","journal-title":"Antimicrob Agents Chemother"},{"key":"760_CR23","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","volume":"58","author":"MW Fried","year":"2013","unstructured":"Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00eeve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918\u201329.","journal-title":"Hepatology"},{"key":"760_CR24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669\u201379.","journal-title":"Gastroenterology"},{"key":"760_CR25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403\u201313.","journal-title":"Lancet"},{"key":"760_CR26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","volume":"368","author":"F Poordad","year":"2013","unstructured":"Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45\u201353.","journal-title":"N Engl J Med"},{"key":"760_CR27","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445\u201354.","journal-title":"Antimicrob Agents Chemother"},{"key":"760_CR28","doi-asserted-by":"crossref","first-page":"S399","DOI":"10.1016\/S0168-8278(16)00627-9","volume":"64","author":"B Fevery","year":"2016","unstructured":"Fevery B, Vijgen L, Van Eygen V, Jessner W, Corbett C, Schlag M, et al. Consistent simeprevir resistance profile in hepatitis C virus genotype 1-infected patients failing simeprevir interferon-free compared with interferon-containing regimens [abstract]. J Hepatol. 2016;64:S399.","journal-title":"J Hepatol"},{"key":"760_CR29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486\u2013504.","journal-title":"J Hepatol"},{"key":"760_CR30","doi-asserted-by":"crossref","unstructured":"Wyles D, Mangia A, Cheng W, Shafran A, Schwabe C, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol. 2015;62(Suppl. 2):S221.","DOI":"10.1016\/S0168-8278(15)30073-8"},{"key":"760_CR31","doi-asserted-by":"crossref","first-page":"ofw052","DOI":"10.1093\/ofid\/ofw052","volume":"3","author":"B Fevery","year":"2016","unstructured":"Fevery B, Thys K, Van Eygen V, Verbinnen T, Van Rossem E, Buelens A, et al. Pre-existence and persistence of resistant minority hepatitis C virus variants in genotype 1-infected patients treated with simeprevir\/peginterferon\/ribavirin. Open Forum Infect Dis. 2016;3:ofw052.","journal-title":"Open Forum Infect Dis"},{"key":"760_CR32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/infdis\/jiu340","volume":"210","author":"I Dierynck","year":"2014","unstructured":"Dierynck I, Thys K, Ghys A, Sullivan JC, Kieffer TL, Aerssens J, et al. Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study. J Infect Dis. 2014;210:1871\u201380.","journal-title":"J Infect Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-017-0760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T08:42:35Z","timestamp":1496220155000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-017-0760-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1186\/s12985-017-0760-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"type":"electronic","value":"1743-422X"}],"subject":[],"published":{"date-parts":[[2017,5,31]]},"article-number":"101"}}